Our research into ovarian cancer
Our strategy
For the past 120 years, we’ve been making discoveries that have saved countless lives. But we have so much more to do. Our strategy sets out how we'll accelerate progress towards a better future.
Our research is saving lives
Survival from ovarian cancer has almost doubled over the last 40 years in the UK. We’re proud of the role we’ve played in helping more women survive – from developing the drug carboplatin, to identifying mistakes in genes (including BRCA1 and BRCA2) that increase ovarian cancer risk. Almost half of the women diagnosed with ovarian cancer now survive beyond 5 years, but we know we must do more for the women whose cancers don't respond to treatment.
Current research
From studying the biology of ovarian cancer cells in the lab to leading clinical trials testing cutting-edge treatments, our researchers are working hard to ensure more women survive ovarian cancer.
Past research
Thanks to research, we’ve helped change the outlook for women with ovarian cancer.
Patients' stories
Meet people like Amanda who have experienced first-hand how our research is making a difference. The life-saving research we do wouldn’t be possible without your support.
Cancer news
From cutting edge science and debunking myths to patient stories, read the latest news, analysis and opinion on our news site.
Further information
Our strategy
Over the last 40 years, cancer survival in the UK has doubled. In the 1970s just 1 in 4 people survived their disease for 10 years or more. Today 2 in 4 survive.
We want to accelerate progress and see 3 in 4 patients surviving the disease by 2034.